Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- UBS sees dip buyers stepping in to support gold at this level
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $15.95 --0%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 9 | New: 15
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 9 | New: 15
Join SI Premium – FREE
Baird lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining an Outperform rating.
Analyst Michael Ulz notes building momentum with multiple commercial and clinical milestones in 2018.
"Notable catalysts remain on track for UX007, including potential for early filing in FAOD (update mid-2018) and Phase 3 data in Glut 1 DS movement (2H18)," he commented.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adani Enterprises Ltd. (ADE:IN) PT Lowered to INR3,254 at Cantor Fitzgerald
- Western Digital Corp. (WDC) PT Lowered to $625 at Cantor Fitzgerald Amid Capex Concerns
- Aletheia Capital Upgrades KEI Industries Ltd (KEII:IN) to Long
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
